To eliminate delays due to the short funding period in 2017-2018, the first year pilot funding opportunity available through the MMRE will be available to Moffitt faculty only. Research and education funding opportunities available from June 2018 onward will be available to all academic and research institutions in the State of Florida.
Submission Deadlines: Full Application: February 1, 2018 Award Announcements: February 14, 2018 Project Start Date: March 1, 2018 Project End Date: June 30, 2018
Principal Investigator: David J. Drobes, Ph.D. Institution: Moffitt Cancer Center Amount: $75,000 Title of Project: Establishing a Research Program on Medical Marijuana and Tobacco Co-Use Abstract: HB 307 (Medical Use of Cannabis) was signed into law in the State of Florida in March, 2016. Although the law and its provisions are in an early phase of implementation, there is concern that increased marijuana use resulting from its passage could have unintended health and/or social consequences for Florida citizens. One area of concern relates to the high degree of comorbidity between marijuana and tobacco use. As tobacco use is among the top preventable causes of disease and death in the US (including Florida), it is imperative to fully understand how medical marijuana may interact with tobacco usage. To date, most of the data relevant to this issue has been obtained from recreational marijuana users. There remain key gaps in the evidence base regarding how medical marijuana relates to tobacco use and cessation. The overarching goal of the current proposal is to initiate a research program aimed at understanding relationships between medical (and recreational) marijuana and tobacco use. Specifically, this proposal will (1) analyze data previously collected at the Moffitt Cancer Center’s Tobacco Research and Intervention Program (TRIP) to address how marijuana use relates to several markers of tobacco use and addiction (Aim 1), (2) examine responses on the Moffitt Cancer Center’s Electronic/New Patient Questionnaire to establish rates and patterns of marijuana and tobacco co-use among the Center’s patient population (Aim 2), and (3) develop and administer a statewide survey to examine usage, knowledge, and attitudes regarding medical marijuana and its relationship to tobacco use (Aim 3). Fulfilling the proposed aims will begin to establish an infrastructure in support of subsequent extramural applications to continue and expand this line of research, with an ultimate goal to provide critical evidence to relevant stakeholders in Florida regarding the relationship between marijuana and tobacco use.
Principal Investigator: Kathleen M. Egan, Sc.D. Institution: Moffitt Cancer Center Amount: $75,000 Title of Project: Medical Cannabis Use among Glioma Patients Treated at a FL-Based Comprehensive Cancer Center Abstract: Glioma is a devastating tumor of the central nervous system. Headache, nausea, and seizure are among frequent symptoms experienced by glioma patients. Anecdotally, marijuana use is common in this population. With recent passage of Amendment 2 of the FL State Constitution, which decriminalizes marijuana use prescribed by a physician, an increasing number of glioma patients can be expected to become users of medical marijuana (MM). However, little is known about patients’ knowledge and expectations, indications for use, perceived symptom relief, and the long-term risks and possible benefits of MM use in glioma patients. This population presents unique clinical challenges: there is high potential for MM to benefit patients, but also potential for adverse outcomes. In this 4 month pilot study, we propose to establish a foundation for comprehensive, longitudinal investigation of MM use in patients with newly-diagnosed glioma by gathering preliminary MM use data in 40 newly diagnosed glioma patients from neuro-oncology clinics at Moffitt. Prevalence data and predictive data will be collected to gain an understanding of the number and type of glioma patient currently using MM. The project takes advantage of an active protocol for enrolling glioma patients at Moffitt offering a quick launch and rapid enrollment of patients. The team at Moffitt assembled for the project represents complementary expertise vital to the research including Dr. Kathleen Egan, an expert in glioma clinical epidemiology, Dr. Solmaz Sahebjam, a medical oncologist with a practice devoted to glioma patients, and Dr. Maija Reblin a psychologist and expert in the evaluation of health-related quality of life. Results will provide novel insights and important preliminary data addressing the benefits and potential adverse effects of MM in patients with glioma. Work accomplished will also be useful for launching similar initiatives in other cancers at Moffitt and throughout the state of Florida.